P450 pharmacogenetics in indigenous North American populations

Lindsay M. Henderson, Katrina G. Claw, Erica L. Woodahl, Renee F. Robinson, Bert Boyer, Wylie Burke, Kenneth E. Thummel

Research output: Contribution to journalReview article

8 Scopus citations


Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

Original languageEnglish (US)
Article number9
JournalJournal of Personalized Medicine
Issue number1
StatePublished - Mar 1 2018
Externally publishedYes



  • Alaska native
  • Allele frequency
  • American Indian
  • Cytochrome P450
  • Drug metabolism
  • First Nations
  • Inuit
  • Mexican Amerindians
  • Pharmacogenetics

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Henderson, L. M., Claw, K. G., Woodahl, E. L., Robinson, R. F., Boyer, B., Burke, W., & Thummel, K. E. (2018). P450 pharmacogenetics in indigenous North American populations. Journal of Personalized Medicine, 8(1), [9]. https://doi.org/10.3390/jpm8010009